IMTX

Immatics N.V. (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tübingen, Germany. The company went public in December 2018 and focuses on developing innovative T cell receptor (TCR) based immunotherapies for cancer treatment. Immatics operates at the cutting edge of precision oncology, leveraging its proprietary technology platforms to identify cancer-specific targets and develop personalized immunotherapies. The company has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline, Genmab, and previously with Celgene, positioning itself as a leader in the emerging field of TCR-based cancer immunotherapy.